VERSARTIS INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Active:1

Completed:5

Trial Phases

3 Phases

Phase 1:4

Phase 2:4

Phase 3:3

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials

Phase 1

4 (36.4%)

Phase 2

4 (36.4%)

Phase 3

3 (27.3%)

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

Phase 3

Terminated

Conditions: Growth Hormone Deficiency

Interventions: Drug: Somavaratan

First Posted Date: 2017-05-09

Last Posted Date: 2018-03-09

Lead Sponsor: Versartis Inc.

Target Recruit Count: 21

Registration Number: NCT03145831

Locations: 🇺🇸
Eric Humphriss, Menlo Park, California, United States

Open-label Extension Study to Evaluate the Safety of Long-term Twice-monthly Administration of Somavaratan in Adult Growth Hormone Deficiency (AGHD)

Phase 2

Terminated

Conditions: Adult Growth Hormone Deficiency (AGHD)

Interventions: Drug: somavaratan

First Posted Date: 2016-03-25

Last Posted Date: 2023-04-13

Lead Sponsor: Versartis Inc.

Target Recruit Count: 36

Registration Number: NCT02719990

Versartis International Trial in Adults With Long-Acting Growth Hormone

Phase 2

Completed

Conditions: Adult Growth Hormone Deficiency

Interventions: Drug: somavaratan

First Posted Date: 2015-08-18

Last Posted Date: 2022-07-26

Lead Sponsor: Versartis Inc.

Target Recruit Count: 36

Registration Number: NCT02526420

Locations: 🇺🇸
AMCR Institute Inc., Escondido, California, United States
🇺🇸
Therapeutic Research Institute of Orange County, Laguna Hills, California, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 15 locations